StemInov is a clinical stage company, spin-off from Nancy’s Teaching Hospital and Lorraine Region’s Uni.
The company develops an off-the-shelf, allogenic stem cell therapy treatment, in the field of inflammatory pathologies, with a focus on critical care.
The company's lead product candidate “WhartSep” is based on Stem cells from Wharton jelly of the umbilical cord (WJ-MSC) and classified by the EMA (European Medicines Agency) as an ATMP (Advanced-Therapy Medicinal Product).
WhartSep is a new concept in immunomodulation and adaptive medicine thanks to its immunomodulation properties.
Our first indication is the patented treatment of septic shock and ARDS in entry of phase I/IIa
Eric is a serial entrepreneur who combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. He is the CEO of PDC line Pharma
Cell Production GMP Unit Expert
CMC expert in cell and gene therapy
Several GMP accreditations
Pierre Emmanuel CHARLES
Prof. in an Intensive Care Unit of a University Hospital. In charge of designing and conducting experimental and translational research towards sepsis
Roland GORDON BERESFORD
Expert in regulatory affair with experience in ATMP
Intellectual Property management